Clinically, patients with hormone-refractory disease and metastatic prostate cancer has high serum levels of IL-6 in fact, interestingly, it stimulates a crucial biological process in cancer called epithelial-mesenchymal transition (EMT) as well as bone metastasis promoting localization of metastatic prostate cancer cells in the bone in fact IL-6 has been proposed as a new marker of morbidity in prostate cancer men [35]. Here, IL6 is linked to metastatic prostate carcinoma.